Abstract
Introduction: Benign prostatic hyperplasia, one of the most common urological problem in aging man, is a complex disease and is often associated with bothersome LUTS.
Objective: The aim of present study was to assess the efficacy of Tadalafil 5mg once daily in symptomatic improvement of LUTS and erectile function in patient’s with comorbid BPH and ED.
Material and Methods: 34 patients of bothersome LUTS with IPSS>8, Qmax <15 were treated with Tadalafil monotherapy 5mg once daily for a period of 12 weeks.
Observations: Tadalafil therapy (5mg- once daily) resulted in clinically meaningful and statistically significant improvement in LUTS secondary to BPH. Tadalafil improved IPSS, Qmax, PVRU and quality of life index. Statistically significant improvement of IIEF score (mean change; 3.735±1.082) at 12 weeks was observed (p<0.001).
Conclusion: Tadalafil seems to be promising treatment option for patient’s with LUTS secondary to BPH and associated ED.
Keywords/Abbreviations: LUTS– Lower Urinary Tract Symptoms, PVRU–Post Void Residual Urine, ED–Erectile Dysfunction, IPSS – International Prostate Symptom Score, PDE5-Is – Phosphodiaesterase 5 Inhibitors, PFR- Peak Flow Rate, IIEF – International index of Erectile Function.
References
1. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction, the multinational survey of aging male ( MSAM – 7 ). Eur Urol 2003; 44: 637-649.
2. Gacci M, Anderson K E, et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia,Eur Urol 2016; 70(1): 124-133.
3. Gacci M, Corona G, Salvi M, et al. A systemic review and meta- analysis on the use of Phosphodiesterase 5 inhibitors alone or in combination with Alpha blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012 ; 61 : 994 – 1003.
4. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L: Tadalafil administered once daily for lower urinary tract symptoms secondary to Benign Prostatic Hyperplasia, a dose finding study. J Uro 2008;. 180(4):1228-1234.
5. Uckert S , Kuthe A, Jonas U and Stief CG. Characterization and functional relevance of cyclic nucleotide Phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166: 2484.
6. Berger AP, Deibl M, Leonhartsberger N, Bektic J, Horninger W, Fritsche G, et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int 2005; 96: 1073.
7. Vignozzi L, Gacci M, Cellai I, et al. PDE 5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE 5 inhibitors in LUTS. Prostate 2013; 73: 1391 – 1402.
8. Liu L, Zheng S, Han P, Wei Q. Phosphodiesterase 5 inhibitors for lower urinary symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Urology 2011; 77: 123-129.
9. McVary KT, Roehrborn GG, Kaminetsky JC, et al.Tadalafil relieves Lower urinary Tract symptoms secondary to benign Prostatic Hyperplasia. J Urol 2007;177: 1401-1407.
10. Egerdie RB, Aurbach S, Roehrborn CG, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized placebo controlled, double blind study. J Sex med 2012;9(1):271-281.
11. Hunter DJ, et al. Health status and quality of life of British men with lower urinary tract symptoms: results from the SF-36. Urology. 1995;45-(6):962-971.
12. Oelke M, Giuliano F , Mirone V, et al. Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptomps suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo controlled clinical trial. Eur Urol 2012;61:917-925.
13. Dmochowski R, Roehrborn C, Klise S,et al. Urodyanimic effects of once daily Tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia:a randomized placebo controlled 12 week clinical trial. J Urol 2010;183(3):1092-1097.
14. Donatucci CF, Brock GB, Goldfischer ER et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a1-year,open label extension study. BJU Int 2011; 107:1110-1116.
15. Bechara A, Romano S, Casabe A, Haime S, Debola P, Hernandez C and Rey H. Comparative efficacy assessment of Tamsulosin vs Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. Pilot Study J. Sex Med.2008: 5: 2170-2178.
16. Birch NC, Hurst G, Doyle PT. Serial residual volumes in men with prostatic hypertrophy.Br J Urol 1988;62(6):571-575.
DOI: https://dx.doi.org/10.18535/jmscr/v5i7.47
